Biotechnology company Moderna (NASDAQ:MRNA) beat Wall Street’s revenue expectations in Q3 CY2025, but sales fell by 45.4% ...

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.

Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

There was also a positive sign for investors worried about the rapid pace at which the company has been burning through its ...

In the past week, Moderna reported third-quarter 2025 earnings with revenue at US$1.02 billion, down sharply from the ...

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to ...

Mast interviewed more than two dozen former and current Moderna employees, along with analysts, rival executives, investors, and experts in mRNA and vaccines to understand how the company arrived at ...

Moderna, the Massachusetts-based biotech company that rocketed into the global spotlight during the development of its COVID-19 vaccine, announced plans on Thursday to cut costs and refocus on core ...

The company reported $200 million in net losses for the third quarter, but an aggressive and highly successful cost-cutting ...

The shortened trading week that ended on May 31 was a strange one for the vaccine developer Moderna (NASDAQ: MRNA). Biotech stocks generally rise after a product they spent years developing earns ...